Six drugmakers face fines for 340B contract pharmacy violations

Six drugmakers could soon face steep fines over their refusal to discount drug prices for pharmacies that contract with 340B providers. The Health Resources and Services Administration on Wednesday sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi and United Therapeutics, informing them that it has asked the Department of Health and Human Services’ Office of the Inspector General to determine whether they should pay fines for the violations.

Read the source article at Home | Modern Healthcare
2021-09-23 22:12:28